BR112016009931B1 - composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer - Google Patents

composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer Download PDF

Info

Publication number
BR112016009931B1
BR112016009931B1 BR112016009931-1A BR112016009931A BR112016009931B1 BR 112016009931 B1 BR112016009931 B1 BR 112016009931B1 BR 112016009931 A BR112016009931 A BR 112016009931A BR 112016009931 B1 BR112016009931 B1 BR 112016009931B1
Authority
BR
Brazil
Prior art keywords
extract
species
cancer
composition
weight
Prior art date
Application number
BR112016009931-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Saad Harti
Jiawei Liu
Original Assignee
Legacy Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legacy Healthcare Ltd filed Critical Legacy Healthcare Ltd
Publication of BR112016009931B1 publication Critical patent/BR112016009931B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5777—Theobroma, e.g. cocao or cocoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112016009931-1A 2013-11-08 2014-11-07 composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer BR112016009931B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361901631P 2013-11-08 2013-11-08
US61/901,631 2013-11-08
PCT/EP2014/074048 WO2015067759A1 (en) 2013-11-08 2014-11-07 Method for the management of cancer and treatment of cancer comorbidities

Publications (1)

Publication Number Publication Date
BR112016009931B1 true BR112016009931B1 (pt) 2021-02-02

Family

ID=51868963

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009931-1A BR112016009931B1 (pt) 2013-11-08 2014-11-07 composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer

Country Status (16)

Country Link
US (2) US10357531B2 (enExample)
EP (1) EP3065751B1 (enExample)
JP (1) JP6742904B2 (enExample)
KR (1) KR102344748B1 (enExample)
CN (2) CN115350236A (enExample)
AU (1) AU2014345539B2 (enExample)
BR (1) BR112016009931B1 (enExample)
CA (1) CA2928675C (enExample)
DK (1) DK3065751T3 (enExample)
ES (1) ES2777250T3 (enExample)
HK (1) HK1223844A1 (enExample)
MX (1) MX2016006006A (enExample)
PL (1) PL3065751T3 (enExample)
PT (1) PT3065751T (enExample)
RU (1) RU2016117205A (enExample)
WO (1) WO2015067759A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs
WO2017186954A1 (en) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity
EP3886838A4 (en) * 2018-11-30 2022-08-10 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
FR3109881B1 (fr) * 2020-05-07 2022-10-21 Legacy Healthcare Switzerland Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2844614A1 (de) 1978-10-13 1980-05-08 Alfred Czypull Bio-aktiv-haartinktur
JPH04342517A (ja) 1990-07-20 1992-11-30 Yutaka Miyauchi ５α−リダクターゼ阻害剤
CH682217A5 (en) 1991-05-23 1993-08-13 Linda Singer Dolla Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness
FR2706771A1 (en) 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
JP3233813B2 (ja) 1995-03-31 2001-12-04 株式会社マンダム チロシナーゼ生合成促進剤及び白髪改善用又は白髪防止用頭髪用化粧料並びに日焼け用化粧料
DE19533777A1 (de) 1995-09-12 1997-03-13 Walther Aria Ellen Haarwuchsmittel
JP3527584B2 (ja) 1996-01-23 2004-05-17 株式会社ナリス化粧品 養毛・育毛剤
US5773241A (en) 1996-09-05 1998-06-30 Ericsson; Arthur Dale Preparation of bioactive extracts
JP2000044439A (ja) 1998-07-31 2000-02-15 Shiseido Co Ltd 頭皮頭髪用組成物
JP2000247830A (ja) 1999-02-26 2000-09-12 Nagase & Co Ltd エラスターゼ阻害剤
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
US6582702B2 (en) * 2001-07-10 2003-06-24 Alvin Foster Rigby Herbal tonic composition that improves respiration, aids in the elimination of toxins and improves overall vitality
US20030077336A1 (en) 2001-10-10 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing flaxseed oil
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
BR0203591A (pt) * 2002-09-05 2004-05-25 Marc Kipfer Bebida reidratante e energética natural a base de água-de-coco, sucos de frutas e componentes nutritivos incorporados
DE102004011968A1 (de) 2004-03-10 2005-09-29 Henkel Kgaa Präbiotisch wirksame Pflanzenextrakte
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
KR20070022018A (ko) 2004-03-19 2007-02-23 네스텍소시에테아노님 기능성 재료의 전달
US20060018867A1 (en) 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
WO2005120452A1 (en) 2004-06-07 2005-12-22 Katica Pavlovic A procedure in production of a curative creams for regeneration of skin tissue, easer breathing, psoriasis, pains and tiredness in legs
FR2865132A1 (fr) 2004-07-06 2005-07-22 Oreal Utilisation de la diosmetine, d'un de ses derives ou d'un extrait de plante contenant l'un d'eux pour favoriser la pigmentation de la peau et/ou des cheveux
DE202004012348U1 (de) 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem
US7462595B2 (en) * 2004-09-17 2008-12-09 Prange Jr Arthur Jergen Methods for treating cancer-related fatigue
JP2006104098A (ja) 2004-10-04 2006-04-20 Ichimaru Pharcos Co Ltd ヒアルロニダーゼ活性阻害剤
FR2877219B1 (fr) 2004-10-28 2007-03-09 Fatima Basri Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene
FR2877576B1 (fr) 2004-11-08 2007-03-09 Ahmed Kadri Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes
DE102005010142A1 (de) 2005-03-02 2005-11-03 Dr. Kurt Wolff Gmbh & Co. Kg Mittel zur Aktivierung der Haarwurzeln und Verwendung des Mittels
JP4804805B2 (ja) 2005-06-10 2011-11-02 横関油脂工業株式会社 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤
WO2008015341A2 (fr) 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2912310B1 (fr) * 2007-02-13 2009-08-07 Kasan Sarl Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
US8088431B2 (en) * 2007-03-14 2012-01-03 The Hershey Company Health bars and compositions for improving mental and physical energy
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
FR2939646B1 (fr) 2008-12-12 2017-04-14 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un orthodiphenol, un sel metallique, du peroxyde d'hydrogene, du (bi)carbonate et un agent alcalinisant
RU2567801C2 (ru) * 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
WO2011005311A1 (en) * 2009-07-07 2011-01-13 Robert Shorr Pharmaceutical composition
WO2012017361A2 (en) 2010-08-05 2012-02-09 Legacy Healthcare Holding Ltd Method for stimulating hair growth
CN103533945A (zh) * 2011-02-23 2014-01-22 传世健康护理有限公司 预防化疗和放疗诱发的脱发（cria）、降低cria影响和改善cria后毛发再生表象的组合物的新用途
WO2012140013A2 (en) 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs

Also Published As

Publication number Publication date
CA2928675A1 (en) 2015-05-14
CA2928675C (en) 2023-09-05
PL3065751T3 (pl) 2020-07-13
KR102344748B1 (ko) 2021-12-30
EP3065751A1 (en) 2016-09-14
AU2014345539A8 (en) 2016-05-26
EP3065751B1 (en) 2019-12-18
US20190314441A1 (en) 2019-10-17
PT3065751T (pt) 2020-03-06
ES2777250T3 (es) 2020-08-04
MX2016006006A (es) 2016-07-18
US10357531B2 (en) 2019-07-23
HK1223844A1 (zh) 2017-08-11
WO2015067759A1 (en) 2015-05-14
AU2014345539B2 (en) 2020-04-23
CN115350236A (zh) 2022-11-18
CN105682671A (zh) 2016-06-15
JP6742904B2 (ja) 2020-08-19
US20160256512A1 (en) 2016-09-08
AU2014345539A1 (en) 2016-05-19
DK3065751T3 (da) 2020-03-09
JP2016535753A (ja) 2016-11-17
KR20160074006A (ko) 2016-06-27
RU2016117205A (ru) 2017-12-11
RU2016117205A3 (enExample) 2018-08-09

Similar Documents

Publication Publication Date Title
US20190314441A1 (en) Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities
Cai et al. Intralymphatic chemotherapy using a hyaluronan–cisplatin conjugate
Pang et al. Intranasal temperature-sensitive hydrogels of cannabidiol inclusion complex for the treatment of post-traumatic stress disorder
CN103191185B (zh) 一种退热凝胶
TWI598104B (zh) Use of Antrodia cinnamomea extract to improve side effects of chemotherapy
CN111228287A (zh) 淫羊藿黄酮苷类化合物在制备治疗黑色素瘤的药物中的应用
CN111346081A (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
CN105560331A (zh) 一种用于抗皮炎湿疹的药物及其制备方法和应用
CN107281242A (zh) 八宝丹及其制剂在制备抑制炎症组织增生药物中的应用
CN107158399A (zh) 两亲性纳米药物及其制备方法和应用
CN105434446A (zh) 一种雷公藤甲素中药复方涂膜剂及其制备方法、应用
HK40077741A (en) Method for the management of cancer and treatment of cancer comorbidities
CN105193810B (zh) 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用
CN111450110A (zh) 牛膝多糖在制备预防非小细胞肺癌转移药物中的应用
KR102766591B1 (ko) 지방분해용 주사제 조성물
CN103705547A (zh) 一种灵芝孢子的破壁处理剂
CN102552916B (zh) 水杨酸钠的新用途
CN111840523B (zh) 一种含活性蛋白和活性脂肪酸的抗癌症的药物组合物
RU2586043C1 (ru) Способ профилактики и лечения осложнений при лучевой терапии рака кожи
RU2211042C1 (ru) Способ лечения местно-распространенного рака гортани
Wang et al. Experimental study of realgar on tumor suppression in lymphoma model
CN105534999A (zh) 一种用于治疗肿瘤的药物组合物及其应用
CN103860561B (zh) 一种防治乳腺癌的药物组合物及其应用
CN102872328A (zh) 一种用于治疗慢性咽炎的药物及其制备方法
CN113209244A (zh) 一种治疗胰腺癌的中药组合物

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: LEGACY HEALTHCARE (SWITZERLAND) SA (CH)